Document is current
Any future updates will be listed below
-
Authors
Parbo, Peter
Madsen, Lasse Stensvig
Ismail, Rola
Zetterberg, Henrik
Blennow, Kaj
Eskildsen, Simon F.
Vorup-Jensen, Thomas
Brooks, David J.
-
Funding
Funding for this research was provided by:
Lundbeck Foundation
Danish Council of Independent Research
Olav Thon Foundation
Swedish Research Council
European Research Council
NEURODIN, Aarhus University Research Foundation
- License Information
-
More Information
Article History
Received: 19 May 2019
Accepted: 23 December 2019
First Online: 2 January 2020
Ethics approval and consent to participate
: The project was approved by the regional ethics committee, and all subjects gave their written informed consent.
: All subjects involved and the authors gave their consent for publication of these findings.
: PP and RI declare that they have no competing interests. HZ has served on scientific advisory boards for Roche Diagnostics, Wave, Samumed, and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (unrelated to the current study). TV-J has received a personal fee from Roche and research grants from the Danish Multiple Sclerosis Society (unrelated to the current study). DJB received research grants from the Danish Council for Independent Research and the Lundbeck Foundation during the conduct of the study. He is a Consultant for GE Healthcare and Biogen™, and has served on Advisory Boards and received personal fees from AstraZeneca, Cytox, Shire, Novartis, GSK, Navidea, UCB, and Acadia. He has been awarded research grants and non-financial support from the Medical Research Council (UK), Alzheimer’s Research Trust (UK), Michael J Fox Foundation, and the European Commission (unrelated to the current study).
